课题基金 / 基金详情

The role of oligodendrocyte progenitor cells in neuroinflammation

The role of oligodendrocyte progenitor cells in neuroinflammation
少突胶质祖细胞在神经炎症中的作用
批准号:
10355928
负责人:
Alban P Gaultier
金额:
$46.27万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2021
资助国家:
美国
项目状态:
已结题
起止时间:
2021-04-01 至 2023-03-31

项目摘要

项目成果

Alban P Gaultier的其他基金

相似基金

相关文献

中文摘要
翻译
摘要: 中枢神经系统(CNS)有三类主要的胶质细胞:星形胶质细胞、小胶质细胞和 少突胶质细胞。最近,第四类胶质细胞被发现,称为少突胶质前体细胞。 (OPC)。与小胶质细胞一样,OPC也具有星状形态,并且是平铺的,横跨整个 格雷和白质。在很长一段时间里,我们对OPC功能的视野局限于成熟的一代 少突胶质细胞。最近发表的研究表明,OPC可以发挥作用,这一教条受到了挑战 其他角色(S)在CNS。事实上,一项新的工作正在揭示这些细胞在 炎症的背景。例如,OPC已被证明表达细胞因子并参与 外周血单核细胞的募集。受伤后,OPC可以释放IL-33,这是一种协调的关键警报蛋白 免疫反应。最后,在多发性硬化症的动物模型中,OPC已被证明呈现抗原和反应 炎性细胞因子,这表明它们是多发性硬化症疾病的积极调节因素。 数据表明,OPC不是简单的旁观者,而是可以参与炎症反应的 中枢神经系统。我们的长期目标是阐明OPC在中枢神经系统中的作用,重点是它们的交替免疫 功能,努力开发新的多发性硬化症疗法。 这一建议的基础是观察到低密度脂蛋白受体与 蛋白-1(LRP1)由OPC表达,具有促进髓鞘吞噬和抗原交叉吞噬的功能。 演示文稿。我们的初步数据显示,OPC中LRP1的缺失促进了动物模型的重新髓鞘形成 我们的中心假设是,在脱髓鞘过程中,OPC将抗原交叉递送到CD8T细胞 以LRP1依赖的方式,导致OPC细胞死亡,损害再髓鞘形成。以Strong为指导 证据,这一假说将通过追求三个具体目标来解决:1:评估LRP1在 OPC介导的炎症反应,2:评估OPC抗原的药理和遗传操作 促进髓鞘修复的交叉递呈,3:确定OPC抗原交叉递呈对T细胞的影响 细胞功能。我们将使用体内脱髓鞘动物模型(铜酮和EAE)和体外培养的 OPC和T细胞来验证我们的假设。我们的方法是创新的,因为它将利用新的老鼠品系 以及启动单细胞测序的状态,以产生关于OPC的替代功能的新的科学知识 在重新髓鞘形成的背景下。 这项拟议的研究意义重大,因为它将测试通过LRP1呈递的抗原是否代表 治疗多发性硬化症和其他脱髓鞘疾病的新靶点。从我们的研究中获得的见解 研究将导致在理解OPC如何促进炎症方面取得根本性进展。
英文摘要
ABSTRACT: The central nervous system (CNS) is home to three major classes of glia: astrocytes, microglia, and oligodendrocytes. Recently, a fourth class of glia has been recognized, called oligodendrocyte progenitor cells (OPCs). Like microglia, OPCs have a stellate morphology and are “tiled”, spanning defined territories across the gray and the white matter. For a long time, our vision of OPC function was limited to generation of mature oligodendrocytes. This dogma is challenged by recently published studies suggesting that OPCs could serve other role(s) in the CNS. Indeed, a nascent body of work is uncovering an intricate role for these cells in the context of inflammation. For example, OPCs have been shown to express cytokines and participate in the recruitment of peripheral monocytes. Following injury, OPCs can release IL-33, a key alarmin that orchestrates the immune response. Finally, in animal models of MS, OPCs have been shown to present antigen and respond to inflammatory cytokines, suggesting that they are active regulators of disease in MS. Taken together, these data demonstrate that OPCs are not simple bystanders, but could participate in the inflammatory response in the CNS. Our long-term goal is to shed light on the role of OPCs in the CNS, focusing on their alternate immune functions, in an effort to develop novel MS therapeutics. The foundation of this proposal is formed by the observations that low-density lipoprotein receptor-related protein-1 (LRP1) is expressed by OPCs and functions to facilitate phagocytosis of myelin and antigen cross- presentation. Our preliminary data show that deletion of LRP1 in OPCs promotes remyelination in animal models of MS. Our central hypothesis is that, during demyelination, OPCs cross-present antigens to CD8 T cells in an LRP1 dependent manner, leading to OPC cell death and impairing remyelination. Guided by strong evidence, this hypothesis will be addressed by pursuing three specific aims: 1: Assess the role of LRP1 in the OPC-mediated inflammatory response, 2: Assess pharmacological and genetic manipulation of OPC antigen cross-presentation in promoting myelin repair, 3: Determine the impact of OPC antigen cross-presentation on T cell functions. We will use in vivo animal models of demyelination (cuprizone and EAE) and in vitro cultures of OPCs and T cells to test our hypothesis. Our approach is innovative because it will utilize novel mouse strains and state of the start single-cell sequencing to generate new scientific knowledge of alternate functions of OPCs in the context of remyelination. The proposed research is significant because it will test whether antigen presentation via LRP1 represents a novel target for therapy development in MS and other demyelinating disorders. The insights gained from our studies will lead to fundamental advances in understanding how OPCs contribute to inflammation.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Understanding the impact of Clusterin on the oligodendrocyte lineage in AD
  • 批准号:
    10539074
  • 项目类别:
  • 资助金额:
    $162.15万
  • 财政年份:
    2022
  • 负责人:
    Alban P Gaultier
  • 依托单位:
Discovering new therapies to promote myelin repair
  • 批准号:
    10314338
  • 项目类别:
  • 资助金额:
    $44.0万
  • 财政年份:
    2021
  • 负责人:
    Alban P Gaultier
  • 依托单位:
NOVO-118 as a therapeutic to promote remyelination in in vivo models of MS
  • 批准号:
    10011900
  • 项目类别:
  • 资助金额:
    $35.41万
  • 财政年份:
    2019
  • 负责人:
    Alban P Gaultier
  • 依托单位:
Meningeal immunity - a middleman between gut microbiome and the brain
  • 批准号:
    9337061
  • 项目类别:
  • 资助金额:
    $43.95万
  • 财政年份:
    2015
  • 负责人:
    Alban P Gaultier
  • 依托单位:
海外基金